<i id='A79F3B78F9'><strike id='A79F3B78F9'><tt id='A79F3B78F9'><pre id='A79F3B78F9'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Cancer drug shortages should be causing more outrage 
Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk 
Novavax promises a turnaround & Lilly roils the obesity market 
FDA approves Leqembi, a milestone in Alzheimer’s treatment 
Medical leaders decry Supreme Court decision on affirmative action 
With fresh data, a dynamic duo powers Eli Lilly to new heights
Medical leaders decry Supreme Court decision on affirmative action 
New safety details link Apellis eye drug to rare cases of blindness 
Duchenne breakthrough therapy leaves behind pioneering families 
What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant? 
United colonoscopy coverage change 'may cost lives,' doctors say 
Neutralizing antibodies against HIV shows promise in children 
Biden outlines 'new path' to provide student loan relief after Supreme Court rejection 
Wildfire pollution widens asthma inequities on Long Island 
Guidelines to prevent youth baseball injuries need more muscle 
